Cytometry News and Research

RSS

Novel antibody test for SARS-CoV-2

A team of researchers in the United States have developed highly specific and sensitive assays that could improve understanding of the antibody response in coronavirus disease 2019 (COVID-19) and help to determine the effectiveness of vaccines.

9 Jul 2020

New technique reduces cell damage, improves IVF rates

Motile sperm are difficult to collect with a conventional cell sorter because they are vulnerable to physical damage.

2 Jul 2020

Important new findings on T cell immunity in COVID-19

Researchers at the Karolinska University Hospital and University Hospital of Wales report that people who have recovered from asymptomatic or mild cases of coronavirus disease 2019 (COVID-19) may have long-term T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Jul 2020

Irresistin: a ‘poison arrow’ to defeat antibiotic resistance

News-Medical speaks to Dr. James Martin and Dr. Zemer Gitai from Princeton University about their research which led to the discovery of a new antibiotic.

1 Jul 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response

Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.

14 Jun 2020

Early neutralizing response to SARS-CoV-2 dominated by IgA antibodies

Researchers from France and the U.S. demonstrated how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could induce an early and vigorous virus-specific IgA response that paves the way for the production of SARS-CoV-2 IgG antibodies, with even better neutralizing properties. Their paper is currently available on the medRxiv preprint server.

14 Jun 2020

Study reveals novel mechanism that triggers a cell-mediated immune response

Viruses and other disease-causing microbes influence the type of immune response their hosts will develop against them. In some cases, the predominant response involves antibodies, proteins made by the immune system that specifically recognize parts of the invading microbe and mediate its destruction.

11 Jun 2020

Females mount stronger T-cell response to SARS-CoV-2

A new study published on the preprint server medRxiv in June 2020 shows that immune cells, antibody levels, cytokine levels, and viral loads contribute to the sex difference seen in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Jun 2020

Study investigates potential of adoptive cell therapy in combination with checkpoint inhibitors

Volume 11, Issue 22 of @Oncotarget reported that there are rationale and evidence supporting immune therapy in Ovarian Cancers.

10 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Tumors cause disruption of the immune system throughout the body, study finds

Cancer treatment has advanced with the advent of immunotherapies that, in some cancers, can overcome tumors' ability to evade the immune system by suppressing local immune responses.

3 Jun 2020

CBD treatment improves arthritis symptoms in dogs, study finds

A team led by researchers at Baylor College of Medicine in collaboration with Medterra CBD conducted the first scientific studies to assess the potential therapeutic effects of cannabidiol for arthritic pain in dogs, and the results could lead the way to studying its effect in humans.

28 May 2020

Characterizing immune cells in malignant brain tumors

It is not always possible to completely remove malignant brain tumors by surgery so that further treatment is necessary.

28 May 2020

TissueGnostics achieves milestone in research community

TissueGnostics is pleased to announce achieving a new level of confidence within the international biomedical research community. As of May 2020, TissueGnostics has been referenced in over 1,500 individual research publications. High impact research made possible by TissueGnostics, emerging from 59 countries on 6 continents, results in a sum impact factor of 8,700.

From TissueGnostics 26 May 2020